New drug targets tough cancers with rare gene mutation
NCT ID NCT07170293
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests a drug called tunlametinib in 15 adults with advanced solid tumors that have a specific change in the NRAS gene and have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth. Participants will take the drug by mouth and be monitored for side effects and how long the benefit lasts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical Unversity Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.